Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3397002 | Clinical Microbiology and Infection | 2012 | 5 Pages |
Abstract
We analysed the 12-week virological response to protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy in 1108 patients carrying B or non-B human immunodeficiency virus (HIV)-1 subtypes with matched resistance mutation patterns. Response rates were not significantly different for non-B and B subtypes stratified for treatment status (51.5% vs. 41.5% in naïve patients; 46.7% vs. 38.7% in experienced patients) or regimens (46.9% vs. 39.7% with PI; 56.7% vs. 40% with NNRTI). No difference in response was detected in patients harbouring B and non-B subtypes with any resistance profile. Further studies are advisable to fully test this approach on larger datasets.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
M. Franzetti, M. Violin, G. Casazza, G. Meini, A. Callegaro, P. Corsi, F. Maggiolo, A.R. Pignataro, S. Paolucci, N. Gianotti, D. Francisci, R. Rossotti, G. Filice, T. Carli, M. Zazzi, C. Balotta,